Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29128000 | 0.84 | KMT2A (0.72) | MEN1KMT2ACYP19A1CYP1A2CYP3A4 | |
| SCHEMBL14902028 | 0.81 | MEN1 (0.71) | MEN1KMT2ACYP19A1CYP1A2CYP3A4 | |
| SCHEMBL19826871 | 0.77 | KMT2A (0.54) | MEN1KMT2ACYP19A1CYP1A2CYP3A4 | |
| SCHEMBL25547142 | 0.74 | CA12 (0.83) | MEN1KMT2ACYP19A1CYP1A2CYP3A4 | |
| SCHEMBL12406975 | 0.74 | KMT2A (1.00) | MEN1KMT2ACYP19A1CYP1A2CYP3A4 | |
| SCHEMBL5960052 | 0.74 | CA12 (0.71) | MEN1KMT2ACYP19A1CYP1A2CYP3A4 | |
| SCHEMBL3925035 | 0.74 | CA12 (0.71) | MEN1KMT2ACYP19A1CYP1A2CYP3A4 | |
| SCHEMBL23451385 | 0.73 | ALDH1A1 (0.60) | MEN1KMT2ACYP1A2CYP3A4CA12 | |
| SCHEMBL12530337 | 0.73 | MEN1 (0.64) | MEN1KMT2ACYP19A1CYP1A2CYP3A4 | |
| SCHEMBL29019359 | 0.73 | MEN1 (0.56) | MEN1KMT2ACYP19A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885CYP19A1 4008/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MEN1 348/4885KMT2A 2081/4885CYP19A1 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.